📰 Escalation Study News
Escalation Study News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Escalation Study. Real-time updates on events, politics, business and more.
May 17, 2024
HONG KONG, SHANGHAI and FLORHAM PARK, N.J., May 17, 2024 -- HUTCHMED Limited today announces that topline and subgroup results from the ESLIM-01 Phase III study of sovleplenib, as well as new...
May 17, 2024
Investegate announcements from HUTCHMED Data to be Presented at EHA2024 Congress
February 29, 2024
NEW YORK, Feb. 29, 2024 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS” or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel
February 20, 2024
/PRNewswire/ -- Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application...
December 1, 2023
CAMBRIDGE, Mass., Dec. 01, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal gene...
December 1, 2023
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Foghorn® Therapeutics Inc. (Nasdaq: FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal
November 2, 2023
-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic...
November 2, 2023
-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T Cell Therapy, WU-CART-007, in Hard-to-Treat T-ALL/LBL Patients
October 16, 2023
Event-free survival of investigational use of Libtayo® (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be...
October 15, 2023
16.10.2023 - Event-free survival of investigational use of Libtayo (cemiplimab) in neoadjuvant cutaneous squamous cell carcinoma (CSCC) from Phase 2 trial to be featured in oral presentation First data for the investigational combination of Libtayo and ...